Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

17 Aug 2006 07:44

Stanelco PLC17 August 2006 Stanelco PLC17 August 2006 Stanelco PLC ("Stanelco" or "the Company") 17 August 2006 Trading update The Company announced on the 14th July 2006 in its interim results for the sixmonth period ending 30 April 2006 that its closing cash position at 30 April2006 was GBP0.3m. The Company started the period with a cash balance of GBP4.4mand made investments in research and development of GBP0.6m and increased itslevels of stock from GBP2.6m at the year end to GBP3.1m. The Company alsoinvested GBP1.2m in capital expenditure in the period. Since the half year end, the Company raised GBP3.7m (net of expenses) by way ofan equity placing in June 2006 of which GBP1.6m was used to meet a stage paymentfor the acquisition of Biotec and GBP2.1m was for working capital purposes. Ofthat GBP2.1m, GBP2.0m has been used for the ongoing commercialisation of theGroup's technologies and meeting the Group's operational running expenses since1 May 2006, and GBP0.1m has been used for capital expenditure. The Company also stated in those interim results that it was considering itsfunding requirements and funding options for the next phase of its development.As at today's date the Company has cash at bank of GBP0.9m with an unusedoverdraft facility of GBP0.2m. The Company estimates that its current cash at bank of GBP0.9m, together withprojected receivables and working capital needs is sufficient to meet its cashrequirements for a further three months in the absence of further funding or newrevenue streams commencing in the period. Since 2000, Stanelco's business model has transformed from a manufacturer andsupplier of capital goods into an intellectual property company with interestsin markets with significant growth potential, which include sustainablepackaging and environmentally responsible sealing solutions for the packagingindustry. As indicated in the interim results, in order to enable the Group to move intothe next phase of the commercialisation of its intellectual property portfolioand to meet its working capital requirements, the Company is currently exploringall financing options including a public equity issue. The Company will update the market once any further information is available. Martin Wagner, Stanelco Chief Executive said: "While the Company is exploring all of its financing options, it continues toactively progress the commercialisation of its products. The Company is in advanced negotiations with a number of potential joint venturepartners in the USA to compound biodegradable resin. This is to meet thedemands currently expressed to Stanelco by major multiple retailers and globalfast food chains. Letters of intent with two of these companies have beenexchanged and the Company believes that these will lead to contracts in theshort term. We acknowledge that Stanelco has encountered delays in rolling out GREENSEAL tothe market. The delays have primarily resulted from the limitations of the foodpackaging industry to allow access to machines to test the technology in afactory environment. The Board believes that these delays will not impact onthe potential success of the project." Contact Martin WagnerChief Executive02380 867 100 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20217:00 amRNSContract
17th Mar 20217:00 amRNSUpdate on biodegradable tree shelter project
16th Mar 20217:00 amRNSBiome commits to UN Race to Zero climate campaign
28th Jan 20217:00 amRNSTrading Update
13th Jan 20217:00 amRNSUpdate on biodegradable tree shelter project
31st Dec 20201:30 pmRNSTotal Voting Rights
15th Dec 20207:00 amRNSBiome's RF division gains traction
11th Dec 20208:05 amRNSAdmission of Subscription Shares
6th Nov 20204:41 pmRNSSecond Price Monitoring Extn
6th Nov 20204:35 pmRNSPrice Monitoring Extension
4th Nov 20207:00 amRNSBiome starts biodegradable tree shelter project
30th Oct 20205:00 pmRNSTotal Voting Rights
30th Oct 20207:00 amRNSDirector/PDMR Shareholding
29th Oct 20207:01 amRNSAppointment of Group Chief Financial Officer
29th Oct 20207:00 amRNSTrading Update
22nd Oct 202012:28 pmRNSHolding(s) in Company
19th Oct 20202:17 pmRNSHolding(s) in Company
12th Oct 20204:07 pmRNSResult of General Meeting
1st Oct 202010:55 amRNSHolding(s) in Company
24th Sep 20207:05 amRNSProposed Fundraise of £1.1 million & Notice of GM
24th Sep 20207:00 amRNSInterim Results
26th Aug 20207:00 amRNSGrant funding from Innovate UK
19th Aug 20207:00 amRNSOrder for compostable bioplastic for coffee pods
30th Jul 20207:00 amRNSTrading Update
25th Jun 20203:46 pmRNSResult of Annual General Meeting
2nd Jun 202010:35 amRNSNotice of Annual General Meeting 2020
22nd Apr 20207:00 amRNSTrading Update
20th Apr 20202:16 pmRNSAnnual Report and Accounts
16th Apr 20207:00 amRNSFinal Results 2019
25th Mar 20207:00 amRNSUpdate re Final Results, 2019 Annual Report & AGM
13th Feb 20204:01 pmRNSNotification of awards under the 2017 LTIP
30th Jan 20204:10 pmRNSShare option awards in lieu of historic bonuses
30th Jan 20207:00 amRNSTrading statement and Board change
4th Nov 20197:00 amRNSBiome to present at Mello London 2019
31st Oct 20195:30 pmRNSTotal Voting Rights
31st Oct 20197:00 amRNSTrading update
30th Sep 20193:04 pmRNSResult of General Meeting
12th Sep 20197:05 amRNSProposed Placing to raise £1.3 million
12th Sep 20197:00 amRNSInterim Results
22nd Jul 20197:00 amRNSTrading Update
25th Jun 20199:17 amRNSLong Term Incentive Plan Second Vesting
17th Jun 20194:12 pmRNSDirector/PDMR/PCA Shareholding
14th Jun 20197:00 amRNSBioplastics Product Update
24th Apr 20191:59 pmRNSResult of Annual General Meeting
24th Apr 20197:00 amRNSTrading Update
4th Apr 201912:20 pmRNSDirector/PDMR/PCA Shareholding
29th Mar 20199:22 amRNSNotice of AGM and Annual Report
28th Mar 20197:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.